National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Am J Prev Med. 2019 Jun;56(6):875-881. doi: 10.1016/j.amepre.2018.12.003. Epub 2019 Apr 17.
U.S. hospital discharges for opioid overdose increased substantially during the past two decades. This brief report describes 90-day readmissions among patients discharged from inpatient stays for opioid overdose.
In 2018, survey-weighted analysis of hospital stays in the 2016 Healthcare Cost and Utilization Project National Readmissions Database yielded the national estimated proportion of patients with opioid overdose stays that had all-cause readmissions within ≤90 days. A multivariable logistic regression model assessed index stay factors associated with readmission by type (opioid overdose or not). Number of readmissions per patient was assessed.
More than 24% (n=14,351/58,850) of patients with non-fatal index stays for opioid overdose had at least one all-cause readmission ≤90 days of index stay discharge and 3% (n=1,658/58,850) of patients had at least one opioid overdose readmission. Less than 0.2% (n=104/58,850) of patients had more than one readmission for opioid overdose. Patient demographic characteristics (e.g., male, older age), comorbidities diagnosed during the index stay (e.g., drug use disorder, chronic pulmonary disease, psychoses), and other index stay factors (Medicare or Medicaid primary payer, discharge against medical advice) were significantly associated with both opioid overdose and non-opioid overdose readmissions. Nearly 30% of index stays for opioid overdose included heroin, which was significantly associated with opioid overdose readmissions.
A quarter of opioid overdose patients have ≤90 days all-cause readmissions, although opioid overdose readmission is uncommon. Effective strategies to reduce readmissions will address substance use disorder as well as comorbid physical and mental health conditions.
在过去的二十年中,美国因阿片类药物过量而住院的人数大幅增加。本简要报告描述了因阿片类药物过量住院患者出院后 90 天内的再入院情况。
2018 年,对 2016 年医疗保健成本和利用项目国家再入院数据库中的住院数据进行了调查加权分析,得出了全国范围内因阿片类药物过量住院患者在 90 天内所有原因再入院的估计比例。多变量逻辑回归模型评估了与再入院类型(阿片类药物过量或非阿片类药物过量)相关的指数住院因素。评估了每位患者的再入院次数。
超过 24%(n=14351/58850)的非致命性阿片类药物过量指数住院患者在指数住院出院后 90 天内至少有一次全因再入院,3%(n=1658/58850)的患者至少有一次阿片类药物过量再入院。不到 0.2%(n=104/58850)的患者因阿片类药物过量而多次再入院。患者人口统计学特征(例如,男性,年龄较大)、指数住院期间诊断出的合并症(例如,药物使用障碍、慢性肺部疾病、精神病)以及其他指数住院因素(医疗保险或医疗补助主要支付人、未经医嘱出院)与阿片类药物过量和非阿片类药物过量再入院均显著相关。近 30%的阿片类药物过量指数住院包括海洛因,这与阿片类药物过量再入院显著相关。
尽管阿片类药物过量再入院并不常见,但四分之一的阿片类药物过量患者在 90 天内有全因再入院。减少再入院的有效策略将解决物质使用障碍以及合并的身体和心理健康状况。